RAC1 and melanoma: Although further experiments involving single agent arms and pharmacodynamic analysis of the effects of avutometinib/FAKi co-inhibition on Rac1-driven melanomas are needed, these preliminary in vivo observations support the potential utility of avutometinib/defactinib for Rac1-driven, therapy resistant melanoma.